home

LATEST ONCOPRESCRIBE UPDATES

• Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer

• First-Line Time Limited Venetoclax Combinations in Chronic Lymphocytic Leukemia

• Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

• LONSURF® Plus Bevacizumab Improves Overall Survival in Advanced Refractory Colorectal Cancer

• HER2DX Genomic Assay Predicts Pathological Response in Early Stage HER2-Positive Breast Cancer

• Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline

• ORSERDU® for ESR-1 Mutated Advanced Breast Cancer

• BRUKINSA® for First Line Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Molecular Tidbits

NEW REGIMENS ADDED

Research Regimens

• TIBSOVO® - for Acute Myeloid Leukemia

• Single Agent LUMAKRAS® - for Non Small Cell Lung Cancer

• KEYTRUDA® - for Malignant Melanoma

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• KEYTRUDA® plus INLYTA® - for Renal Cancer

• PARAPLATIN® and VEPESID® with TECENTRIQ® - for Small Cell Lung Cancer

• IMFINZI® Consolidation - for Locally Advanced Non Small Cell Lung Cancer

• CABOMETYX® - for Renal Cancer

Curbside Consultation

Lung Cancer Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• TTP, HUS and aHUS: Different diseases – Different treatments

• HER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE